Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505
Sterling Winthrop's x-ray contrast agent Omnipaque recorded global sales of more than $500 million last year, according to a listing of the world's 100 best selling drugs published in the May issue of Med Ad News. The agenthad worldwide sales of $505 million and was ranked 37th on thepublication's list.
The majority of Omnipaque's revenue derived from U.S. sales,which were pegged at $480 million in 1993 -- up 1% from the $475million in sales recorded the year before.
The next best selling imaging agent on the list was Bristol-MyersSquibb's Isovue. The x-ray imaging product recorded worldwidesales of $310 million in 1993, down 7.4% from the $335 millionregistered in 1992. Isovue had U.S. sales of $305 million in 1993and $320 million the year before.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.